Is UnitedHealth a Buy for Long-Term Investors?

UnitedHealth Group's stock has declined over 40% this year, making it the worst-performing stock in the Dow, driven by a downward revision in EPS guidance from $28.15-$28.65 to $24.65-$25.15 due to higher Medicare Advantage utilization rates and reimbursement struggles in Optum Health. The stock is trading near a five-year low amid a DOJ investigation regarding fraudulent Medicare billing, which the company denies, and the resignation of its CEO; however, insider buying suggests confidence in a return to growth, potentially making it a buying opportunity for long-term investors.

Analysis

UnitedHealth Group (UNH) shares have declined over 40% year-to-date, making it the Dow Jones Industrial Average's poorest-performing stock. This significant stock price deterioration is primarily linked to a downward revision in its full-year 2024 earnings per share (EPS) guidance; management initially guided for $28.15 to $28.65 per share in January but lowered this forecast to $24.65 to $25.15 following the first-quarter earnings report on April 17. Two principal factors underpin this revision: higher-than-anticipated utilization rates in its Medicare Advantage businesses, which are inflating near-term costs and impacting profitability, and reimbursement challenges within its Optum Health division due to Medicare cuts and evolving insurance plan structures in certain markets. Further unsettling investors, CEO Andrew Witty resigned about a month after the Q1 earnings release, and The Wall Street Journal reported a Department of Justice (DOJ) investigation into alleged fraudulent Medicare billing, a claim UnitedHealth's management has refuted as "deeply irresponsible." Consequently, UNH shares are trading near a five-year low, around $300 as of June 3, with its forward price-to-earnings (P/E) ratio now comparable to peers Humana and Cigna, a significant compression from its prior premium. Despite these headwinds, management stated during the Q1 release and CEO resignation announcement that the company should return to growth by next year, a view potentially supported by recent insider transactions, including a $25 million stock purchase by the new CEO, Stephen Hemsley, and an additional $6.6 million by other executives, signaling internal confidence in long-term prospects.

Key Decisions for Investors

• Investors should weigh the significantly compressed valuation and recent insider buying against the ongoing operational challenges, including Medicare Advantage utilization and Optum reimbursement pressures, as well as the uncertainty stemming from the CEO transition and DOJ investigation.
• Long-term investors might find the current share price an attractive entry point, particularly if management's projection for a return to growth materializes, but should remain vigilant regarding near-term volatility and further developments on the cost and regulatory fronts.
• Monitoring future earnings reports for stabilization in utilization trends and Optum's performance, alongside any updates on the DOJ probe, will be crucial in assessing the company's recovery trajectory.